BostonGene, a leading provider of AI-driven solutions for molecular and immune profiling, has announced a collaboration with LegoChem Biosciences, Inc. (LCB), a clinical-stage biopharmaceutical company specializing in the development of next-generation antibody-drug conjugates (ADCs). They will work together to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers. This study is taking place at prestigious cancer institutions in the United States and Canada to evaluate the safety and initial effectiveness of LCB84, both as a standalone treatment and in combination with an immune checkpoint inhibitor (anti-PD-1 antibody).

Stephen Slocum, PhD, Director of Drug Development at LegoChem Biosciences, explained their reason for partnering with BostonGene, stating, "Our collaboration with BostonGene aims to validate theories about the mechanisms of ADC efficacy and discover new biomarkers to enhance patient selection. This partnership is crucial as LegoChem Biosciences continues to validate our ADC platform technology for safer and more effective cancer treatments. BostonGene's integrated analytic and AI capabilities will provide us with invaluable insights for the development of innovative cancer therapies."

Andrew Feinberg, President and CEO at BostonGene, expressed his enthusiasm about the collaboration with LCB, saying, "We are excited to collaborate with LCB to support the development of their novel, TROP2-directed ADC, LCB84, and address the substantial unmet need in cancer treatment by improving tumor targeting, safety, and efficacy."

Nathan Fowler, MD, Chief Medical Officer, highlighted BostonGene's unique strengths, stating, "BostonGene’s proprietary discovery platform combines in-depth knowledge of the human immune system and cancer biology with exceptional software expertise and capacity. We have a pragmatic, results-oriented team approach, driven by the potential to make a direct impact on the lives of cancer patients. Our accelerated biomarker discovery algorithms facilitate the optimized matching of patients with therapies that can effectively target the unique characteristics of their cancer."

In this collaboration, BostonGene will serve as the central laboratory and analytic partner for exploratory biomarkers. They will conduct comprehensive multi-omic profiling of patients' tumor tissue and blood samples, including whole-exome sequencing (WES), whole-transcriptome sequencing (RNAseq) of tumor tissue from matched tumor biopsies in the study, and immunoprofiling to identify hundreds of different cell types from a single blood sample. Leveraging their advanced AI and machine learning platforms, BostonGene will provide comprehensive analytics to identify predictive biomarkers and optimize the selection of patients most likely to benefit from treatment.

Each patient's tumor possesses a unique molecular "fingerprint," which can be identified using BostonGene's differentiated analytic and software platforms. These platforms offer real-time, cost-efficient results to support the delivery of highly personalized cancer therapies, offering patients the best chance of durable responses.

 

Source: businesswire.com

Report Abuse